［1］Boquete M, Carballada F.Childhood asthma and viral infection: interactions and therapeutic possibilities［J］. Allergol Immunopathol (Madr), 2001, 29(3): 133-140.

［2］Hallstrand TS, Moody MW, Wurfel MM, Schwartz LB, Henderson WR Jr, Aitken ML. Inflammatory basis of exercise-induced bronchoconstriction［J］.Am J Respir Crit Care Med, 2005, 172(6): 679-686.

［3］Davis BE, Illamperuma C, Gauvreau GM,  Watson RM, O′Byrne PM, Deschesnes  F, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses［J］. Eur Respir J, 2009, 33(6): 1302-1308.

［4］Jackson DJ. The role of rhinovirus infections in the development of early childhood asthma［J］. Curr Opin Allergy Clin Immunol, 2010, 10(2)：133-138.

［5］Gern JE. The urban environment and childhood asthma study［J］. J Allergy Clin Immunol, 2010, 125(3): 545-549.

［6］Li J, Luo DF, Li SY, Sun BQ, Zhong NS. Efficacy of intramuscular BCG polysaccharide nucleotide on mild to moderate bronchial asthma accompanied with allergic rhinitis: a randomized, double blind, placebo-controlled study［J］.Chin Med J (Engl), 2005, 118(19): 1595-1603.

［7］Lakomski PG, Chitre M. Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan［J］.J Manag Care Pharm, 2004, 10(2): 115-121.

［8］Lee DK, Haggart K, Currie GP, Anderson SD, Lipworth BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis［J］. Br J Clin Pharmacol, 2003, 55(6): 639-642.

［9］Baki A, Orhan F. The effect of loratadine in exercise-induced asthma［J］. Arch Dis Child, 2002, 86(1): 38-39.

［10］Peroni DG, Piacentini GL, Pietrobelli A, Loiacono A, De Gasperi W, Sabbion A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children［J］. Eur Respir J, 2002, 20(1): 104-107.

［11］Yang YH, Lin YT, Lu  MY, Tsai MJ, Chiang BL. A double-blind, placebo-controlled, and randomized study of loratadine (Clarityne) syrup for the treatment of allergic rhinitis in children aged 3 to 12 years［J］. Asian Pac J Allergy Immunol, 2001, 19(3): 171-175.

［12］Nash DB, Sullivan SD, Mackowiak J. Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting［J］. Am J Manag Care, 2000, 6(1 Suppl): S3-S15.

［13］Reicin A, White R, Weinstein SF, Finn AF Jr, Nguyen H, Peszek I, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma［J］. Arch Intern Med, 2000, 160(16): 2481-2488.

［14］Roquet A, Dahlen B, Kumlin M, Ihre E, Anstren G, Binks S, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics［J］. Am J Respir Crit Care Med, 1997, 155(6): 1856-1863.

［15］Liao E, Leahy M, Cummins G. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis［J］. Am J Manag Care, 2001, 7(15 Suppl): S459-S468.

［16］赵京. 变应原特异性免疫治疗［J］.实用儿科临床杂志，2008，23(9)： 646-648.